Spots Global Cancer Trial Database for Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial

Official Title: IIT2021-07-Atkins-CARMA: Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial

Study ID: NCT05403736

Conditions

Cancer

Interventions

Cardiac Aggressive Risk MitigAtion Plan

Study Description

Brief Summary: The purpose of this study is to examine adherence to cardio-oncology consultation.

Detailed Description: The purpose of this study is to evaluate patient participation in a plan to improve heart health after radiation therapy by having a cardio-oncology assessment early during cancer treatment. Cardiologists and cancer doctors will review any cardiovascular risk factors (heart conditions, hypertension, bleeding disorders, smoking history, obesity, cholesterol and diabetes) and develop a personalized treatment plan. In addition, the study will evaluate use of wearable devices such as a FitBit, and remote EKG (Omron EVOLV) and blood pressure monitoring (AliveCor KardiaMobile) devices to monitor participant's health. Blood will be drawn at three separate timepoints for biomarker testing of heart injury, aging, inflammation and metabolism. Study visits will occur at baseline, weekly during radiation therapy, 6 weeks and 3 months after completion of radiation therapy.